| Meaghan Moxley, | |
|
650 Mchenry Rd Ste 3300, Aberdeen, MD 21001-2682 | |
| (443) 843-6100 | |
| Not Available |
| Full Name | Meaghan Moxley |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 9 Years |
| Location | 650 Mchenry Rd Ste 3300, Aberdeen, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669869632 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Umd Upper Chesapeake Medical Center | Bel air, MD | Hospital |
| University Of Md Harford Memorial Hospital | Havre de grace, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upper Chesapeake Endocrinology Associates, Llc | 2466529011 | 8 |
News Archive
The Chinese Center for Disease Control and Prevention (China CDC) and Fred Hutchinson Cancer Research Center today formalized an ongoing relationship by signing a collaboration agreement. It marks the first such agreement between the China CDC and a U.S. cancer research center.
Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.
Researchers in Italy have discovered how specific versions of a protein called Numb protect the key tumor suppressor p53 from destruction.
Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Entity Name | Upper Chesapeake Endocrinology Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366639312 PECOS PAC ID: 2466529011 Enrollment ID: O20080923000613 |
News Archive
The Chinese Center for Disease Control and Prevention (China CDC) and Fred Hutchinson Cancer Research Center today formalized an ongoing relationship by signing a collaboration agreement. It marks the first such agreement between the China CDC and a U.S. cancer research center.
Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.
Researchers in Italy have discovered how specific versions of a protein called Numb protect the key tumor suppressor p53 from destruction.
Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Meaghan Moxley, 1250 E Marshall Street, Box 980163, Richmond, VA 23298 Ph: (804) 828-9357 | Meaghan Moxley, 650 Mchenry Rd Ste 3300, Aberdeen, MD 21001-2682 Ph: (443) 843-6100 |
News Archive
The Chinese Center for Disease Control and Prevention (China CDC) and Fred Hutchinson Cancer Research Center today formalized an ongoing relationship by signing a collaboration agreement. It marks the first such agreement between the China CDC and a U.S. cancer research center.
Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.
Researchers in Italy have discovered how specific versions of a protein called Numb protect the key tumor suppressor p53 from destruction.
Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).
› Verified 1 days ago
Prashant Rohit Shukla, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 998 Hospitality Way, Suite 102, Bayside Internal Medicine, Llc, Aberdeen, MD 21001 Phone: 410-297-9500 Fax: 410-297-9016 | |
Dr. Nischinta Thapa, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 650 Mchenry Rd Ste 3300, Aberdeen, MD 21001 Phone: 443-843-6100 | |
John Merren Byrne, D.O. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 995 Hospitality Way, Aberdeen, MD 21001 Phone: 410-306-7880 | |
Smita Massey-gomez, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 995 Hospitality Way, Aberdeen, MD 21001 Phone: 410-306-7880 | |
Dr. Anuraag Sood, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 19 Walnut Ln, Aberdeen, MD 21001 Phone: 410-272-3233 Fax: 410-273-9465 | |
Dr. Joseph K Llanos, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1429 Viridian Rd, Aberdeen, MD 21001 Phone: 240-205-1694 |